Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26068491.
- Also identified by DOI 10.1016/j.ijrobp.2015.02.016 and PMC identifier 4816453.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combining the latest targeted biologic agents with the most advanced radiation technologies has been an exciting development in the treatment of cancer patients. Stereotactic body radiation therapy (SBRT) is an ablative radiation approach that has become established for the treatment of a variety of malignancies, and it has been increasingly used in combination with biologic agents, including those targeting angiogenesis-specific pathways. Multiple reports have emerged describing unanticipated toxicities arising from the combination of SBRT and angiogenesis-targeting agents, particularly of late luminal gastrointestinal toxicities. In this review, we summarize the literature describing these toxicities, explore the biological mechanism of action of toxicity with the combined use of antiangiogenic therapies, and discuss areas of future research, so that this combination of treatment modalities can continue to be used in broader clinical contexts.
Medical subject headings
- Angiogenesis Inhibitors
- Gastrointestinal Tract
- Neoplasms
- Radiosurgery